17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮
17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮 性质
| 沸点 | 453.4±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.152±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 14.82±0.60(Predicted) |
| 颜色 | 白色至米白色 |
17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮 用途与合成方法
Ki: 20.4 nM (Human androgen receptor)
EC50: 1.35 nM (Human androgen receptor)
11-Ketodihydrotestosterone (11-KDHT; 1-10 nM; 24 hours; LNCaP and VCaP cells) treatment induces significant cell proliferation.
11-Ketodihydrotestosterone (11-KDHT; 0.1-10 nM; 7-10 days; LNCaP and VCaP cells) treatment results in the significant upregulation of
KLK3
,
TMPRSS2
and
FKBP5
in both LNCaP and VCaP cells, with the exception of
KLK3
at 1 nM in LNCaP cells.
In PNT2 cells, only 20% of 11β-hydroxyandrostenedione (11OHA4) and 11β-hydroxytestosterone (11OHT) are metabolised with the former yielding 11keto-androstenedione (11KA4), 11-Ketodihydrotestosterone (11-KDHT) and 11β-hydroxy-5α-androstanedione (11OH-5αDIONE) and the latter yielding 11OHA4, 11KT and 11-Ketodihydrotestosterone with downstream products <0.03 μM.
In prostate cancer tissue, C11-oxy C19 metabolites at significantly higher levels than the C19 steroids are detected, with unconjugated 11-Ketodihydrotestosterone, 11KT and 11OHA4 levels ranging between 13 and 37.5 ng/g. Analyses of total steroid levels in plasma show significant levels of 11OHA4 (≈230-440 nM), 11KT (≈250-390 nM) and 11-Ketodihydrotestosterone (≈19 nM).
Cell Proliferation Assay
| Cell Line: | LNCaP and VCaP cells |
| Concentration: | 0.1 nM, 1 nM or 10 nM |
| Incubation Time: | 7 days (LNCaP cells) or 10 days (VCaP cells) |
| Result: | Induced significant cell proliferation. |
RT-PCR
| Cell Line: | LNCaP and VCaP cells |
| Concentration: | 1 nM, 10 nM |
| Incubation Time: | 24 hours |
| Result: | Resulted in the significant upregulation of KLK3 , TMPRSS2 and FKBP5 in both LNCaP (Fig 3) and VCaP (Fig 4) cells. |
17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-135794 | 17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮 | 32694-37-4 | 1 mg | 1590 |
| 2026-06-05 | HY-135794 | 17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮 | 32694-37-4 | 5mg | 3500 |
